Management of severe complications in Behçet's disease with TNF inhibitors. (3rd July 2017)

• Record Type: Journal Article
• Authors: Desbois, A. C.; Vallet, H.; Domont, F.; Comarmond, C.; Cacoub, P.; Saadoun, D.
• Is Part Of: Expert opinion on biological therapy. Volume 17:Number 7(2017:Jul.)
• Page Start: 853
• Page End: 859
• Publication Date: 2017-07-03
• Subjects: Anti-TNFα agents -- infliximab (IFX) -- adalimumab (ADA) -- Behcet's disease (BD) -- treatment; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2017.1328496
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : The efficacy of anti-TNFα agents has been recently evaluated in many studies in Behçet's disease (BD), particularly in ocular and life-threatening manifestations such as neurological and vascular disease. Areas covered : The following article aims to summarize the currently available efficacy and safety data of anti-TNFα agents in BD. Expert opinion : Most studies have shown dramatic and rapid efficacy with anti-TNFα agents on the main BD-associated issues including posterior uveitis, gastro-intestinal and neurological complications as well as major vessel disease. Experts in the field do recommend the use of anti-TNF agents (either infliximab or adalimumab) as a first-line therapy in severe posterior uveitis in BD and now use anti-TNFα treatment in BD-associated life threatening manifestations. However, data is mainly based on retrospective cohorts or open-label prospective studies. Controlled studies (versus conventional immunosuppressants such as azathioprine and cyclophosphamide) are warranted to properly evaluate their efficacy as first line therapeutic in life-threatening manifestations of BD.